-
Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
By Fraiser Kansteiner Nov 14, 2024 2:13pm As sales of Novo Nordisk’s GLP-1 drugs for diabetes and […]
-
NIH, MSKCC researchers publish AI model for predicting immunotherapy responses
Researchers at Memorial Sloan Kettering Cancer Center and the National Institutes of Health’s National Cancer Institute said their AI approach was able to identify patients more likely to have objective responses to immune checkpoint inhibitors as well as forecast short- and long-term survival among different cancers. (Getty Images)
-
ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
A new trend has emerged at this year’s American Society of Clinical Oncology conference: the possibility of replacing decades-old chemotherapy with novel approaches. “We want to be part of that wave,” AbbVie Pedro Valencia, Ph.D., AbbVie’s vice president of solid tumor pipeline strategy and execution, told Fierce Biotech onsite in Chicago. “This is the ASCO…
-
8 Biotech Companies in Chicago Cultivating the City’s Life Sciences Scene
Considering Chicago has long been seen as a healthcare hotbed, it’s no surprise that the city’s biotech sector has been strengthening over the past several years. Biotech Companies in Chicago to Know Tempus Cardiosense AbbVie CancerIQ
Biotech
Archive
Categorise
Recent Posts
- Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
- NIH, MSKCC researchers publish AI model for predicting immunotherapy responses
- ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
- Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
- 8 Biotech Companies in Chicago Cultivating the City’s Life Sciences Scene
